Select Page

Stopping the clock on diabetes!

Abarceo Pharma has identified a novel diabetes target located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their insulin again, naturally. Abarceo is in the preclinical phase of drug development.

Your Title Goes Here

You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Rapidus: Diabetes companies collect SEK 21.5 million

Diabetesbolag tar in 21, 5 miljoner kroner
– Denmark, March 01, 2021

Almi Invest investerar i Abarceos nya diabetesbehandling

– Denmark, March 01, 2021

Management

Kristian Hansen

Kristian Hansen

CEO

Claes Wollheiim

Claes Wollheiim

CSO